ASH 2021 Focus on CAR T-Cell Therapy
Featured articles
ASH 2021 Focus on CAR T-Cell Therapy Podcast
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
CONTENTS
Online First
CAR T-cell Therapy
Most re-hospitalisations within first month from CAR T-cell infusion
CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL
High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma
Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL
Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma
CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL
Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma
Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma
